CCR5 and HIV-1 infection: Interestingly, an ongoing clinical trial (NCT03517631) is evaluating the efficacy and safety profile of autologous CD34+ cells that stably express multiplexed shRNAs targeting CCR5 and the HIV-1 genome to fight HIV-1 infection.